U.S. based Johnson & Johnson found itself in the top 5 R&D spenders among pharmaceuticals with a 15.5% increase over the previous year's spending which translates into $5.4 bn Eur. Ranked #1 in sales, Johnson & Johnson expect 21 new drug filings or approvals over the next 3 years; five of which are expected by the end of this year.
Pending Approval:
Concerta - Adult ADHD
Remicade - Pediatric Ulcerative Colitis, UC colectomy avoidance
Ceftobiprole - Complicated Skin and Skin Structure Infections
Doribax - Nosocomial Pneumonia
TMC125 - NNRTI HIV/AIDS treatment-experienced patients
Phase III:
Invega (paliperidone ER OROS) - Bipolar mania
Paliperidone palmitate IM long acting injectable - Schizophrenia
Risperdal Consta - Bipolar maintenance, Deltoid injection
Carisbamate - Epilepsy
Topomax - Pediatric exclusivity
CNTO 1275 (ustekinumab) - Psoriasis
CNTO 148 (golimumab) - Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis Rheumatoid Arthritis
Procrit - Chronic Renal Function
Ceftobiprole - Nosocomial Pneumonia, Hospitalized community acquired pneumonia
Doxil - Breast Cancer
Velcade - Non-Hodgkin's Lymphoma, Multiple Myeloma 1st line
Yondelis - Relapsed Ovarian Cancer
Dacogen - Injection Myelodysplastic Syndromes
Prezista - Naïve & early experienced patients
Tapentadol - Moderate to severe acute pain (IR formulation), moderate to severe chronic pain (ER formulation)
Rivaroxaban VTE Prophylaxis, knee replacement surgery, stroke prevention in atrial fibrillation, VTE treatment
[Source: FierceBiotech]
.jpg)
Comment Preview